A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC

SPLENDOUR: Survival improvement in lung cancer induced by denosumab therapy

Denosumab is a monoclonal antibody targeting and inhibiting RANKL, a protein that acts as the primary signal for bone resorption. The trial was designed to investigate the potential of denosumab added to standard treatment (chemotherapy) compared to standard treatment alone to increase survival of patients with advanced NSCLC with or without bone metastasis in advanced unselected treatment-naïve patients.

After the excellent initial recruitment, the accrual rate has dramatically slowed down, potentially due to more attractive treatment alternatives for this patient population, in the context of a competitive landscape of ongoing immune-oncology clinical trials. The trial Steering Committee has therefore decided to close the recruitment prematurely. No safety concerns led to this decision.

Trial Scheme


Trial Information

Primary Endpoint:
Overall survival
Secondary Endpoints:
Progression free survival 
Objective response
Toxicities of treatment 
Evaluation of potential predictive biomarkers for denosumab activity 
Target Sample Size:
1000 Patients 
Final Accrual:
595 Patients
Protocol Release Date:
27 May 2014
Trial Activation Date:
18 August 2014
First Patient In:
12 January 2015
Accrual Closure Date:
10 January 2018
Global Trial Completion Date:
10 September 2018

Trial Organisation

ETOP Trial Chair:
Solange Peters
Coordinating Group:
European Organisation for Research and Treatment of Cancer (EORTC)
Participating Countries:
Austria, Belgium, France, Germany, Ireland, Italy, Poland, Slovenia, Spain, Switzerland, United Kingdom
EudraCT number: 2013-003156-21
ClinicalTrials.gov: NCT02129699


ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland